Mutual of America Capital Management LLC Sells 10,889 Shares of Abbott Laboratories $ABT

Mutual of America Capital Management LLC lessened its stake in shares of Abbott Laboratories (NYSE:ABT) by 5.5% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 188,339 shares of the healthcare product maker’s stock after selling 10,889 shares during the period. Mutual of America Capital Management LLC’s holdings in Abbott Laboratories were worth $25,226,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. IMG Wealth Management Inc. increased its holdings in Abbott Laboratories by 759.1% in the 2nd quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock valued at $26,000 after buying an additional 167 shares during the period. Anfield Capital Management LLC boosted its holdings in shares of Abbott Laboratories by 81.3% in the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock valued at $32,000 after purchasing an additional 104 shares in the last quarter. Delos Wealth Advisors LLC bought a new position in shares of Abbott Laboratories in the 2nd quarter valued at $32,000. Curio Wealth LLC lifted its position in shares of Abbott Laboratories by 15,250.0% during the 2nd quarter. Curio Wealth LLC now owns 307 shares of the healthcare product maker’s stock worth $42,000 after buying an additional 305 shares during the last quarter. Finally, Pineridge Advisors LLC grew its position in Abbott Laboratories by 34.6% in the second quarter. Pineridge Advisors LLC now owns 315 shares of the healthcare product maker’s stock valued at $43,000 after acquiring an additional 81 shares during the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.

Abbott Laboratories Stock Down 1.1%

Abbott Laboratories stock opened at $107.46 on Monday. The firm has a 50 day moving average price of $124.77 and a two-hundred day moving average price of $128.29. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.24 and a current ratio of 1.70. Abbott Laboratories has a 52-week low of $105.78 and a 52-week high of $141.23. The firm has a market cap of $186.86 billion, a price-to-earnings ratio of 28.89, a PEG ratio of 1.78 and a beta of 0.72.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting the consensus estimate of $1.50. Abbott Laboratories had a return on equity of 17.94% and a net margin of 14.72%.The business had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. During the same quarter last year, the firm posted $1.34 earnings per share. The firm’s revenue was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Equities analysts predict that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Thursday, January 15th will be given a dividend of $0.63 per share. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.59. The ex-dividend date of this dividend is Thursday, January 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. Abbott Laboratories’s payout ratio is currently 67.74%.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: MedTech and pharma strength, and EPS resilience — Abbott reported adjusted Q4 EPS growth (company highlighted margin improvements) and strong MedTech (+~12%) and Established Pharma (+~9%) performance that partly offset Nutrition weakness; management still projects FY‑2026 adjusted EPS growth. Press Release
• Positive Sentiment: Analysts keep buy/outperform stance despite cuts — several major firms trimmed price targets after the print but largely maintained buy/overweight ratings, signaling conviction in the longer‑term story even as near‑term expectations were tempered. Analyst Reaction
• Positive Sentiment: Some commentators view the pullback as a buying opportunity — market commentators highlight ABT’s dividend history, cash flow and buyback capacity, suggesting the drop may create an attractive entry for long‑term investors. MarketBeat: Pullback Analysis
• Neutral Sentiment: Full earnings call and transcripts available — investors can review management commentary and segment detail in the Q4 earnings call transcript for color on nutrition, diagnostics and Exact/other strategic items. Earnings Transcript
• Neutral Sentiment: Dividend/valuation commentary circulates — value and dividend‑focused outlets are flagging ABT as attractively valued after the pullback; this is background context rather than a near‑term catalyst. Zacks: Value Take
• Negative Sentiment: Revenue miss driven by Nutrition and Diagnostics — Q4 revenue (~$11.5B) fell short of consensus, with Nutrition down sharply (~8–9%) and Diagnostics weak, sparking the initial selloff. Reuters: Revenue Miss
• Negative Sentiment: Guidance slightly below Street — Abbott set Q1 EPS and FY‑2026 EPS ranges that sit near or a touch below consensus, increasing near‑term revenue/growth concerns. Guidance Details
• Negative Sentiment: Multiple price‑target cuts — a raft of firms (Citigroup, Goldman, Raymond James, Sanford Bernstein, Oppenheimer, RBC, etc.) trimmed targets, which can amplify selling pressure even if ratings remain constructive. Benzinga: PT Cuts
• Negative Sentiment: Options and hedging activity spiked — an unusual surge in put buying suggests traders are positioning for further near‑term downside (heightened bearish sentiment).
• Negative Sentiment: Regulatory scrutiny in India — reports of an investigation into alleged misuse of a codeine‑based cough syrup (Abbott Healthcare) add an extra headline risk in emerging markets. Reuters: India Scrutiny

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on ABT shares. Mizuho raised their price target on shares of Abbott Laboratories from $135.00 to $140.00 and gave the company a “neutral” rating in a research note on Tuesday, October 14th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Abbott Laboratories in a research note on Monday, December 29th. Evercore ISI reduced their price objective on Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a research report on Friday. Royal Bank Of Canada cut their price target on Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a research note on Friday. Finally, Daiwa Capital Markets raised their price objective on shares of Abbott Laboratories from $134.00 to $136.00 and gave the company an “outperform” rating in a report on Tuesday, October 21st. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $140.79.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.